The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy inDe NovoRecipients: One-Year Results of a Scandinavian Randomized Trial-Reference-Cited by-同舟云学术

The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy inDe NovoRecipients: One-Year Results of a Scandinavian Randomized Trial

Published:2015-03-17 Issue:7 Volume:15 Page:1967-1975
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:

Author:

Arora S.¹,Andreassen A. K.¹,Andersson B.²,Gustafsson F.³,Eiskjaer H.⁴,Bøtker H. E.⁴,Rådegran G.⁵,Gude E.¹,Ioanes D.²,Solbu D.⁶,Sigurdardottir V.⁷,Dellgren G.⁷,Erikstad I.¹,Solberg O. G.¹,Ueland T.⁸⁹,Aukrust P.⁸⁹¹⁰,Gullestad L.¹¹¹,

Affiliation:

1. Department of Cardiology; Oslo University Hospital Rikshospitalet; Oslo Norway

2. Department of Cardiology; Sahlgrenska University Hospital; Gothenburg Sweden

3. Department of Cardiology; Rigshospitalet; Copenhagen Denmark

4. Department of Cardiology; Aarhus University Hospital; Skejby Denmark

5. The Clinic for Heart Failure and Valvular Disease; Skåne University Hospital and Lund University; Lund Sweden

6. Novartis Norge AS; Oslo Norway

7. Transplant Institute; Sahlgrenska University Hospital; Gothenburg Sweden

8. Research Institute for Internal Medicine; Oslo University Hospital, Rikshospitalet; Oslo Norway

9. K.G. Jebsen Inflammatory Research Center, Faculty of Medicine; University of Oslo; Oslo Norway

10. Section of Clinical Immunology and Infectious Diseases; Oslo University Hospital Rikshospitalet; Oslo Norway

11. K.G. Jebsen Cardiac Research Center and Center for Heart Failure Research; Faculty of Medicine; University of Oslo; Oslo Norway

Funder

Novartis Scandinavia

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Reference23 articles.

1. Calcineurin inhibitors in heart transplantation;Keogh;J Heart Lung Transplant,2004

2. Optimizing the immunosuppressive regimen in heart transplantation;Eisen;J Heart Lung Transplant,2004

3. Treatment of allograft vasculopathy in heart transplantation;Segovia;Expert Opin Pharmacother,2006

4. Proliferation signal inhibitors and cardiac allograft vasculopathy;Raichlin;Curr Opin Organ Transplant,2008

5. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: A 24-month analysis;Vigano;J Heart Lung Transplant,2007

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of autologous regulatory T cell (Treg) therapy to prevent Cardiac Allograft Vasculopathy (CAV) in paediatric heart transplant recipients;Frontiers in Immunology;2024-09-09

2. Going the distance: Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial;The Journal of Heart and Lung Transplantation;2024-08

3. Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients;JACC: Heart Failure;2024-06

4. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines;Circulation;2023-08-29

5. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease;Journal of the American College of Cardiology;2023-08